Biologic Drugs

Sep 27, 2017
By Pharmaceutical Technology Editors
FDA rejected the company’s biologics license application for its anti-rheumatoid arthritis biologic and has requested additional clinical safety data.
Sep 26, 2017
By Pharmaceutical Technology Editors
Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor program for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink.
Sep 26, 2017
By Pharmaceutical Technology Editors
This latest FDA approval expands the blockbuster anti-cancer biologic’s indications in oncology.
Sep 25, 2017
Biopharmaceutical companies developing new competitive biotech therapies have pressed hard for clarity on the testing and data required by FDA to gain market approval of biosimilars that can be filled by a pharmacist without prescriber preapproval.
Sep 21, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.
Sep 19, 2017
By Pharmaceutical Technology Editors
The collaboration with Immunocore, a T cell receptor company, aims to discover and develop immunotherapy molecules to treat infectious diseases.
Sep 15, 2017
By Pharmaceutical Technology Editors
European Medicines Agency’s Committee for Medicinal Products for Human Use grants a positive opinion for the approval of the biosimilar for treating breast cancer.
Sep 15, 2017
By Pharmaceutical Technology Editors
The approval marks the first biosimilar approved in the United States for treating cancers.
Sep 12, 2017
By Pharmaceutical Technology Editors
The company has extended its presence in the US market to support its growing business in the region.
Sep 07, 2017
By Pharmaceutical Technology Editors
Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.
native1_300x100
lorem ipsum